Edition:
United States

People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,465.81GBp
7:42am EST
Change (% chg)

3.50p (+0.24%)
Prev Close
1,462.50p
Open
1,465.50p
Day's High
1,470.00p
Day's Low
1,461.00p
Volume
2,946,882
Avg. Vol
9,191,389
52-wk High
1,745.56p
52-wk Low
1,259.32p

Vallance, Patrick 

Mr. Patrick Vallance is President - Pharmaceuticals R&D of Glaxosmithkline Plc. He joined CET in 2010 and was appointed President, Pharmaceuticals R&D, in January 2012. Prior to this he was Senior Vice President, Medicines Discovery and Development. Patrick joined the company in 2006 as Head of Drug Discovery. Prior to joining GSK Patrick was a clinical academic and led the Division of Medicine at University College London. He has over 20 years’ experience of research clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999. Patrick has been on the Board of the UK Office for Strategic Co-ordination of Health Research (OSCHR) since 2009.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Philip Hampton

522,000

Andrew Witty

6,661,000

Simon Dingemans

3,166,000

Moncef Slaoui

7,324,000

Roger Connor

--

Abbas Hussain

--
As Of  30 Dec 2015